FIDSON Commences Operations in Its Brand New WHO-Complaint Ultra-Modern Facility


Thursday, June 23 2016 1:23PM /NSE

Fidson Healthcare Plc, a major pharmaceutical company in Nigeria has just completed a brand new WHO compliant ultra-modern manufacturing plant, which is arguably the largest pharmaceutical manufacturing facility in Africa.

It is equipped to produce 6 distinct product lines (intravenous infusions and other sterile preparations, tablets, capsules, oral liquids, creams & ointments and dry powder) to contribute immensely to the nation’s medicine needs and proffer opportunities for future exports.

The project is part of the strategic expansion and diversification programme the company started following the successful Private Placement in 2008.

The supply gap existing in the infusion products’ sub-market persists as demand keeps growing linearly with population, which informed Fidson’s foray into the IV fluids market.

• It is estimated that 2% of the population (160m) get admitted to hospitals in Nigeria monthly
   •  About 70% of medical patients get infusions at an average rate of 4 bottles per admission
   •  For surgical patients, over 90% of them will be given infusions

• This translates to 3.2 million admission cases monthly
   •  10.2 million bottles per month
   •  123 million bottles per year
   •  This is expected to increase with the growing population which is currently put at 2.8% per annum

• Market size in revenue terms was conservatively put at N25bn in 2013 (PMAG)

There is an unmet gap of 2,364,000 bottles per month which the new facility is positioned to bridge while growing volumes in the existing production lines including while adding Water for Injection, Ear/Eye Drops lines.

With this new facility, we aim to significantly meet orders of the major consumers - the Teaching & General Hospitals, Federal Medical Centres, Big Private Hospitals, Corporate Clinics, etc as far as infusion products are concerned using the existing marketing and distribution platforms.

The expected financial contribution from this project is such that shall grow the Company’s turnover by additional N1.9 billion at 75% Activity Level by the 3 rd year of production, N2.9 billion at 90% Activity Level by 6th year and N3.6 billion by the 10th year at same 90% Activity Level. Overall, this project shall contribute handsomely to the Overhead Recovery of the Company thereby growing shareholder value significantly. This will be in addition to increased capacities (almost two-fold) for the existing 5 product lines that will open up opportunities for contract manufacturing.

Aside from increasing our production capacity, the new factory would enhance our business prospects in 3 key ways:

1. Ability to tender for WHO sponsored programmes, which Nigerian pharmaceutical manufacturers are unable to access, losing out to foreign companies in these tenders.

2. Opportunity to export some of our products to other countries (Africa and beyond) and grow our FOREX income while also extending affordable quality medicines to some of the poorer nations within the continent.

3. There is also an overarching benefit in job creation as additional 300 jobs are being created.
Overall, profitability is expected to improve as a result of increased efficiency.

Related NEWS
Fidson Healthcare Plc - Tough Operating Conditions Delivers HOLD signal
FIDSON Declares N28.48 mln PAT in Q1 2016 Result SP N2.15k
FIDSON Proposes N0.05k Final Dividend in 2015 Audited Result SP N2.47k
Fidson Healthcare PLC a rose on concrete
Fidson grows PAT by 1.53 as Revenue down by 17.97 in Q3 15 

Related News